Effects of young age at presentation on survival in breast cancer

Saghir, Nagi S. El; Seoud, Muhieddine; Khalil, Mazen K.; Charafeddine, Maya; Salem, Ziad; Geara, Fady; Shamseddine, Ali

doi:10.1186/1471-2407-6-194

Cited by 212 publications

(191 citation statements)

References 18 publications

Supporting

Mentioning

160

Contrasting

Unclassified

Order By: Relevance

“…The difference between the mean age at diagnosis of triplenegative breast cancer was not significant between our study and international studies (52 years versus 50 years), whereas the mean age at diagnosis of breast cancer, independent of phenotype, was 52 years in Lebanon versus 63 years in the U.S. [11][12][13].…”

Section: Discussionmentioning

confidence: 84%

Triple-Negative Breast Cancer in Lebanon: A Case Series

et al. 2011

View full text Add to dashboard Cite

Objectives. To determine the incidence, characteristics, and survival outcomes of triple-negative breast cancer patients in a medical oncology practice in Lebanon.Methods. The pathology reports of all breast cancer cases diagnosed or treated in 1997-2008 were reviewed.Results. One hundred seventy breast cancer cases (9.3%) of the 1,834 cases that were identified in this practice over a 10-year span had a triple-negative phenotype, with a median age at diagnosis of 52 years. The pathology distribution of those cases was as follows: invasive ductal carcinoma, 85%; medullary carcinoma, 5%; invasive lobular carcinoma, 5%; 95 cases (63%) were grade III. At diagnosis, 17% presented with stage I, 47% had stage II, 24% had stage III, and 12% had stage IV disease, whereas 11% had an inflammatory component. After a median follow-up of 17 months, 43 patients (25.3%) had relapsed and the most common sites of relapse were the brain (19%), lungs (19%), and bones (12%). The risk for recurrence peaked at 1.5 years and became almost nil after 3 years. Twenty patients received induction chemotherapy, among whom six (42.9%) had a complete response and six (42.9%) had a partial response to treatment. None of the patients progressed on neoadjuvant chemotherapy. The 5-year disease-free survival rate was 75% for stage I, 58% for stage II, and 40% for stage III patients, whereas the 5-year overall survival rate was 88% for stage I, 72% for stage II, and 63% for stage III patients. Adjuvant therapy was administered to 96% of patients, using a taxane-based regimen in 38% of cases. The median survival time for stage IV patients was 19 months, with a first line taxane-based regimen used in 50% of cases.Conclusions. The incidence of triple-negative breast cancer in Lebanon is similar to that described in the literature. In order to determine targets for future therapeutic options, it is essential to understand the biology of this particular breast cancer subtype. The Oncologist 2011;16: 1552-1556

show abstract

Section: Discussionmentioning

confidence: 84%

Triple-Negative Breast Cancer in Lebanon: A Case Series

et al. 2011

View full text Add to dashboard Cite

show abstract

“…It has become evident that young women with breast cancer have a poorer prognosis than older women; their frequency of recurrence is higher [1,2], and their survival lower [1,[3][4][5][6]. In a recent Danish study of low-risk breast cancer patients enrolled in the Danish Breast Cancer Group (DBCG) 89a-protocol [7], we found that local recurrence was associated with distant metastasis (DM) among younger patients ( 45 years).…”

mentioning

confidence: 99%

Impact of age, intrinsic subtype and local treatment on long-term local-regional recurrence and breast cancer mortality among low-risk breast cancer patients

et al. 2016

View full text Add to dashboard Cite

“…Reviewed the available American data (SEER database), it was found that the mastectomy rate was the highest (58.2%) [16]. Other research also pointed around half of the elder cases (53.1%) above 50 years treated by chemotherapy in compare to younger group (76.5%) [38]. The current study supported that cases of BC treated with a multidisciplinary approach, merging the efforts of surgery, chemotherapy, and radiation therapy based on the BC stages [37].…”

Section: Discussionmentioning

confidence: 99%

“…This is consistence with outdated risk factors for developing BC, which are null parity, early menarche, late pregnancy and menopause, increase intake of diet rich in fat [21]. It was been testified in another study that the incidence of comorbidity disease was 15.4% hypertension, 7.1% diabetes, 34% smoking and the elder BC cases had diabetes, hypertension, and cardiac diseases (P<0.001) [38].…”

Section: Discussionmentioning

confidence: 99%